Featured Research

from universities, journals, and other organizations

Modified HIV May Be Effective For Delivering And Regulating Gene Therapy

Date:
June 27, 2000
Source:
University Of North Carolina At Chapel Hill
Summary:
HIV, the virus that causes AIDS, may be adapted for use in gene therapy to treat genetic diseases and immune system disorders including AIDS itself, according to a University of North Carolina at Chapel Hill scientist.

CHAPEL HILL -- HIV, the virus that causes AIDS, may be adapted for use in gene therapy to treat genetic diseases and immune system disorders including AIDS itself, according to a University of North Carolina at Chapel Hill scientist.

New findings released June 24 in the journal Molecular Therapy provide the first evidence that a genetically stripped-down amalgam of HIV components not only can safely deliver genes to target cells in the body, but can be fashioned with a molecular switch system that turns these genes off in response to a common antibiotic.

This accomplishment was achieved without toxic affects in laboratory rats. It suggests that doctors may someday be able to control gene expression in people who are treated with gene therapy vectors based on HIV.

With such control, genes can be switched off when no longer needed, say, for example, in the production of growth hormone. And if adverse affects develop, gene expression can be curtailed.

The new study was led by Dr. Tal Kafri, assistant professor of microbiology and immunology at the UNC-CH School of Medicine. Kafri conducted the study while he was a postdoctoral scientist with Dr. Inder M. Verma at the Salk Institute in La Jolla, Calif. In earlier experiments, Kafri and others had studied the potential feasibility of gene therapy viral vectors based on lentiviruses, a subfamily of retroviruses. HIV is a lentivirus.

"One advantage of HIV and other lentiviruses is that they can introduce the gene of interest into cells that do not divide, and simple retroviruses cannot do that," Kafri said. "This makes them ideal for delivering genomic material directly into the body because most of our cells do not divide. This is very important for transducing (transferring genetic material to) hemopoietic stem cells (precursor blood cells) because most of them are quiescent and do not divide."

Kafri, a member of UNC-CH’s Gene Therapy Center, said retroviruses are unique in that they can integrate their genome into the host’s genome. "Unlike adenovirus – another virus used as a vector in gene therapy research – you don’t lose the genomic sequence that is incorporated into the host DNA following cell division," he said.

Thus, as hemopoietic stem cells develop, they will continue carrying the gene that was introduced therapeutically via vectors based on HIV.

"Another advantage in using a lentiviral vector is its large capacity," Kafri said. "It’s much larger than a simple retrovirus, which means you can put more genes and more genomic material in the same vector."

To produce his HIV-based vector, Kafri separated the viral genome into several components.

"Each of these alone cannot become a virus, but once together in the cell, one component contributes proteins, another contributes nucleic acid, and the third contributes non-HIV envelope proteins," Kafri said. The molecular switch system and the regulated therapeutic genes can be packaged in the form of RNA for transduction.

In the new study, the vector with its components and payload was injected into the brains of 12 rats. When expressed – switched on – a "reporter gene" for research purposes showed as green fluorescence in brain cells. After the antibiotic doxycycline was added to the animals’ drinking water, fluorescence dramatically diminished. Withdrawal of antibiotic from the drinking water was followed by return of fluorescence.

"These studies show that an inducible lentiviral vector can deliver and regulate transgene expression in vivo," the authors wrote in the journal article. "We believe that regulated gene expression is an essential tool for successful gene therapy approaches."

Kafri said the success of gene therapy would rise and fall with the vector.

"I believe that we have arrived at a point where gene therapists need to make their own basic science," he said. "And we need to direct the basic science toward questions relevant to vectors."

In terms of his lentivirus vector, Kafri said the huge advantage is that it’s the most efficient at transducing hemopoietic stem cells.

"This carries implications for treating blood disorders such as Fanconi anemia, thalassemia and sickle cell anemia; Gaucher’s disease, an inherited enzyme deficiency; and diseases of immune deficiency," he said.

And might that meant targeting HIV? "Sure, if you want to target HIV, a lentivirus vector would be the vector of choice," he said.


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "Modified HIV May Be Effective For Delivering And Regulating Gene Therapy." ScienceDaily. ScienceDaily, 27 June 2000. <www.sciencedaily.com/releases/2000/06/000625232201.htm>.
University Of North Carolina At Chapel Hill. (2000, June 27). Modified HIV May Be Effective For Delivering And Regulating Gene Therapy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/06/000625232201.htm
University Of North Carolina At Chapel Hill. "Modified HIV May Be Effective For Delivering And Regulating Gene Therapy." ScienceDaily. www.sciencedaily.com/releases/2000/06/000625232201.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins